FibroGen Inc
FGEN
FibroGen Inc AI Insights
Informational only. Not investment advice.Snapshot
- Negative equity (-17M) with 118M cash - company technically insolvent but has 3+ years runway at current -17M FCF burn rate[Common Stockholders Equity]
- Net income of 216M TTM despite -38M operating loss suggests one-time gain (likely asset sale or settlement) masking ongoing losses[Net Income TTM]
- Revenue collapsed 59% over 3 years (8.3M TTM) - commercial viability in serious question[Total Revenue 3Y Growth]
Watch Triggers
- Cash and Equivalents: Falls below 60M (18-month runway) — Triggers forced financing at distressed terms or strategic sale
- Total Revenue TTM: Rises above 20M quarterly run-rate — Would signal commercial traction and extend runway
- Research and Development TTM: Drops below 15M annually — Indicates pipeline abandonment and shift to wind-down mode
Bull Case
Negative EV (-84M) means market assigns zero value to pipeline - any positive clinical news creates asymmetric upside from 34M market cap
R&D spend of 23M TTM (2.8x revenue) indicates active pipeline development despite financial distress
Bear Case
Revenue declined 59% over 3 years with operating margin of -459% - core business is non-viable without transformation
Negative equity and 8.6M interest expense on minimal revenue creates dilution or bankruptcy risk within 3 years
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage FGEN's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway exhaustion within 24-36 months forces binary outcome: partnership, acquisition, or liquidation
- 118M cash vs -17M annual FCF burn
- No clear path to profitability with 8.3M revenue
- Negative equity limits financing options
Public Strategies Rankings
See how FibroGen Inc ranks across different investment strategies.
Leverage FGEN's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
FGEN Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$38.46M | — | ||
$-79.52M | — | ||
0.00 | — | ||
$8.3M | -95.4% | — | |
$-10.86 | — | ||
-459% | -406.2% | — | |
2,599% | +2666.5% | — | |
$-17.09M | — | ||
0.00 | — | ||
Beta 5Y (Monthly) | unknown | — |
FGEN Dividend History
FGEN Stock Splits
FGEN SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/10/25 | 09/30/25 | 10-Q | |
08/11/25 | 06/30/25 | 10-Q | |
05/12/25 | 03/31/25 | 10-Q | |
03/17/25 | 12/31/24 | 10-K | |
11/12/24 | 09/30/24 | 10-Q | |
08/06/24 | 06/30/24 | 10-Q | |
05/06/24 | 03/31/24 | 10-Q | |
02/26/24 | 12/31/23 | 10-K | |
11/06/23 | 09/30/23 | 10-Q | |
08/07/23 | 06/30/23 | 10-Q | |
05/08/23 | 03/31/23 | 10-Q | |
02/27/23 | 12/31/22 | 10-K | |
11/07/22 | 09/30/22 | 10-Q | |
08/08/22 | 06/30/22 | 10-Q | |
05/09/22 | 03/31/22 | 10-Q | |
02/28/22 | 12/31/21 | 10-K | |
11/09/21 | 09/30/21 | 10-Q | |
08/09/21 | 06/30/21 | 10-Q | |
05/10/21 | 03/31/21 | 10-Q | |
03/01/21 | 12/31/20 | 10-K | |
11/05/20 | 09/30/20 | 10-Q | |
08/06/20 | 06/30/20 | 10-Q | |
05/07/20 | 03/31/20 | 10-Q | |
03/04/22 | 12/31/19 | 10-K/A | |
03/02/20 | 12/31/19 | 10-K | |
11/12/19 | 09/30/19 | 10-Q | |
08/08/19 | 06/30/19 | 10-Q | |
05/09/19 | 03/31/19 | 10-Q | |
02/27/19 | 12/31/18 | 10-K | |
11/08/18 | 09/30/18 | 10-Q | |
08/07/18 | 06/30/18 | 10-Q | |
05/09/18 | 03/31/18 | 10-Q | |
02/27/18 | 12/31/17 | 10-K | |
11/08/17 | 09/30/17 | 10-Q | |
08/07/17 | 06/30/17 | 10-Q | |
05/09/17 | 03/31/17 | 10-Q | |
03/01/17 | 12/31/16 | 10-K | |
11/08/16 | 09/30/16 | 10-Q | |
08/08/16 | 06/30/16 | 10-Q | |
05/09/16 | 03/31/16 | 10-Q | |
02/29/16 | 12/31/15 | 10-K | |
11/12/15 | 09/30/15 | 10-Q | |
08/13/15 | 06/30/15 | 10-Q | |
05/12/15 | 03/31/15 | 10-Q | |
03/26/15 | 12/31/14 | 10-K | |
11/14/14 | 09/30/14 | 424B4 | |
10/01/14 | 06/30/14 | S-1 | |
05/12/15 | 03/31/14 | 10-Q | |
11/14/14 | 12/31/13 | 424B4 | |
09/30/13 | 09/30/13 | Unknown | -- |